SVCM
ALNY icon

Saturn V Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Saturn V Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,327
Closed -$1.98M – 22
2023
Q4 		$1.98M Buy
+10,327
New +$1.76M 0.76% 20

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Saturn V Capital Management's ALNY Position: Q1 2024 in Review

Saturn V Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2024, closing a stake of 10,327 shares — an estimated $1.98M sold.

Saturn V Capital Management first reported a position in ALNY in Q4 2023 and held it in 1 quarter. The position peaked at $1.98M in Q4 2023. 498 funds tracked by Wall St. Rank hold ALNY as of Q1 2024.

  • Saturn V Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Saturn V Capital Management sold 10,327 Alnylam Pharmaceuticals shares in Q1 2024, an estimated $1.98M.
  • Saturn V Capital Management first reported a position in Alnylam Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Saturn V Capital Management's Alnylam Pharmaceuticals position peaked at $1.98M in Q4 2023.
  • 498 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2024.

Based on Saturn V Capital Management's 13F filing for Q1 2024, filed 15 May 2024.